Welcome to our dedicated page for Vivos Therapeutics SEC filings (Ticker: VVOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vivos Therapeutics, Inc. (NASDAQ: VVOS) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a medical technology issuer focused on obstructive sleep apnea (OSA) and related sleep-disordered breathing conditions, Vivos uses its SEC reports to describe its business, device portfolio, acquisitions, financing activities and governance matters.
Through periodic reports such as Forms 10-K and 10-Q, investors can review detailed discussions of Vivos’ operations, including its Complete Airway Repositioning and/or Expansion (CARE) devices, DNA appliance, Vivos Guides, VidaSleep oral appliance and related clinical and commercial initiatives. These filings also explain the company’s strategy of acquiring or affiliating with sleep centers, such as The Sleep Center of Nevada, and its revised OSA provider management model that uses jointly owned management entities.
Current reports on Form 8-K and amendments (8-K/A) highlight specific material events, including the completion of acquisitions, integration updates for sleep centers, clinical data announcements, changes to at-the-market offering programs, and the scheduling or results of stockholder meetings. Proxy statements on Form DEF 14A provide additional detail on board composition, equity incentive plans and matters submitted to stockholders for approval.
On Stock Titan, these VVOS filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key sections, such as risk factor updates, acquisition terms, and descriptions of new management or affiliation agreements. Users can also monitor items like late-filing notifications on Form 12b-25 and other compliance-related submissions. Together, the filings and AI analysis offer a structured view of how Vivos reports its evolving sleep apnea device business and sleep center operations to regulators and investors.
Vivos Therapeutics reported results from its 2025 annual meeting. Stockholders elected R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow and Dr. Matthew Thompson to one-year board terms. An amendment to the 2024 Omnibus Equity Incentive Plan was approved with 2,453,436 shares for, 516,368 against and 2,275 abstaining. Baker Tilly US, LLP was ratified as independent auditor with 4,861,139 shares for, 102,827 against and 4,762 abstaining.
Voting eligibility totaled 7,504,807 shares outstanding as of September 8, 2025, with a quorum of approximately 4,968,728 shares represented.
Vivos Therapeutics filed a prospectus supplement updating its at-the-market program under its Form S-3. The company may offer and sell common stock with an aggregate offering price of up to $3,583,686 from time to time through H.C. Wainwright & Co., as sales agent, pursuant to General Instruction I.B.6 of Form S-3.
This update reflects current I.B.6 capacity and excludes approximately $4,605,773 of shares previously sold under the prior prospectus. The public float was approximately $35,068,378, calculated from 7,477,266 non‑affiliate shares at $4.69 per share as of August 26, 2025. Over the past 12 months, the company sold securities with an aggregate market value of approximately $8,105,774 under I.B.6. VVOS last traded at $2.97 on October 23, 2025.
Vivos Therapeutics (VVOS) reported that on October 24, 2025 it filed a prospectus supplement to increase the aggregate offering price of shares issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., dated February 14, 2025. This update expands the capacity available for potential future issuances of common stock through the ATM program after effectiveness as permitted by the prospectus supplement.
The company also filed a legal opinion from Ellenoff Grossman & Schole LLP as Exhibit 5.1, with the related consent included in the same exhibit. VVOS’s common stock trades on The NASDAQ Stock Market LLC.
The filing is a Definitive Proxy Statement for Vivos Therapeutics, Inc. (VVOS) containing meeting and governance disclosures. Only stockholders of record as of September 8, 2025 may vote at the Annual Meeting. The board recommends FOR each director nominee in Proposal 1 and FOR Proposals 2 and 3. The company adopted a revised Insider Trading Policy to reflect changes to SEC Rule 10b5-1 effective February 2023, including pre-clearance by the Chief Financial Officer and specified trading windows. Beneficial ownership disclosures show V-CO Investors 2, LLC holds 828,000 shares (11.03%) and Dawei Luo holds 572,016 shares (7.62%). Executive and director group ownership is disclosed as 157,874 shares (2.10%). The filing also lists director nominees, director fees and various outstanding option grants with grant dates, strike prices and expiration dates.
Vivos Therapeutics, Inc. filed a report noting that it issued a press release on September 17, 2025 announcing first-time peer-reviewed data on its Vivos DNA (Daytime-Nighttime Appliance®) treatment. The data confirms that the device is both safe and efficacious for children suffering from obstructive sleep apnea.
The report mainly serves to formally furnish this scientific and clinical update to the market, with the full details provided in the attached press release filed as Exhibit 99.1.
Vivos Therapeutics has registered a shelf to offer up to $50,000,000 of securities. The registration covers common stock, preferred stock, warrants, subscription rights, debt securities and units. The company’s common stock trades on Nasdaq under the symbol VVOS (last reported sale $4.40 on September 4, 2025).
As of September 4, 2025, there were 7,504,807 shares of common stock issued and outstanding. The prospectus details a pivot from a dentist-focused sales model toward strategic alliances and acquisitions of sleep centers, including the June 2025 acquisition of The Sleep Center of Nevada and a new management agreement in July 2025. The company reports initial SCN integration activity, deployment plans for multiple Sleep Optimization teams, and preliminary case economics.
Vivos Therapeutics filed an amended report to add audited and pro forma financial statements and expanded disclosures for its acquisition of The Sleep Center of Nevada (SCN). On June 10, 2025, Vivos completed the deal, acquiring all operating assets of SCN for a $6.0 million cash payment, 607,287 shares of restricted common stock valued at $1.5 million, and the assumption of specified liabilities, plus a potential $1.5 million earn‑out in stock tied to a financial milestone.
Through long‑term practice administration agreements, Vivos’ subsidiary AIM will manage SCN and a related professional entity in exchange for monthly administration fees of $200,000 and $100,000, and Dr. Prabhu has a $400,000 annual physician employment agreement with bonus potential and board observation rights. Vivos outlines its Sleep Optimization team model, early integration progress, and plans to apply this structure to additional acquisitions and joint management arrangements, while highlighting significant risks, including substantial $8.25 million secured debt, regulatory and reimbursement exposure, labor constraints, and the unproven nature of its new provider‑focused business model.
Vivos Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the second quarter ended June 30, 2025. The company issued this press release on August 19, 2025, and attached it as Exhibit 99.1.
The financial results and related details are contained in the press release, which is incorporated by reference but expressly treated as “furnished” rather than “filed” under the Exchange Act. The filing also includes an iXBRL cover page as Exhibit 104.
Vivos Therapeutics, Inc. (VVOS) reported interim financial results reflecting recent acquisition activity and constrained liquidity. The company completed an acquisition (SCN) with total preliminary consideration of about $8.7 million, including $6.0 million cash, 607,287 restricted shares valued at $1.3 million and contingent earn‑out equity estimated at $1.4 million. Goodwill rose to $5.6 million and identifiable intangible assets of $1.9 million were recorded.
For the six months ended June 30, 2025, the company had revenues reported in the periods shown (examples: $3.8 million and $4.1 million in comparative periods shown), operating losses (e.g., $(4.9) million and $(1.9) million in shown periods) and an accumulated deficit of approximately $113.1 million. Cash and cash equivalents were about $4.4 million with total liabilities of approximately $21.5 million, and management disclosed substantial doubt about the company’s ability to continue as a going concern absent additional financing. The company completed financing transactions in 2024–2025 including private placements and PIPE proceeds totaling several million dollars (including $2.7 million received in June 2025 and $3.7 million upon conversion of a bridge note).
Vivos Therapeutics, Inc. filed a notice that it will submit its Form 10-Q for the quarter ended June 30, 2025 late, using the five-day extension allowed under Rule 12b-25. The delay stems from its June 10, 2025 acquisition of The Sleep Center of Nevada, which requires completion of 2023 and 2024 audits, review of interim financials, and integration of that data into Vivos’ June 30, 2025 quarterly financial statements.
The company indicates that general and administrative expenses for the three months ended June 30, 2025 increased by over 50% compared with the same period in 2024, mainly due to salaries, professional fees, and other costs related to acquiring and integrating the new business. Vivos therefore anticipates a material increase in net loss for the quarter, though it characterizes these acquisition-related costs as one-time items that are not expected to recur once the integration is complete.